This paper addresses pertinent issues concerning the role of physicians in the assessment and treatment of men with complaints of erectile dysfunction. With the availability of safe and effective oral drug therapy, the ®eld of erectile dysfunction has expanded rapidly to encompass multiple disciplines and specialties. Recognizing the need for evidence-based standards and guidelines in the management of this common disorder, a multidisciplinary panel of experts was convened to examine existing literature and practice standards. This panel employed a modi®ed Delphi methodology to develop consensus on de®nition and classi®cation, rational utilization of diagnostic and therapeutic options, and clinical guidelines for the management of erectile dysfunction in a primary care setting. A`Process of Care Model for Erectile Dysfunction' was thus developed, incorporating a step-wise decision making approach, de®ned in terms of relevant processes, actions and outcomes. According to this method, initial assessment should include a careful clinical history, focused physical examination and selected laboratory tests. Subsequent management should be goal-oriented, taking into account patient and partner needs and preferences. The stepwise treatment algorithm is based on the selection criteria of ease of administration, reversibility, relative invasiveness and cost. In addition, common referral indications for specialized diagnostic testing and treatment are provided. By assisting the primary physician in selecting appropriate assessment tools and treatment interventions, the proposed guidelines are intended to optimize care of the patient with erectile dysfunction.
Erectile dysfunction is a signi®cant and common medical problem. 1 In the Massachusetts Male Aging Study (MMAS), a community-based survey of men between the ages of 40 and 70 y, 2 52% of respondents reported some degree of erectile dif®culty. Complete erectile dysfunction, de®ned as the total inability to obtain or maintain erections during sexual stimulation, as well as the absence of nocturnal erections, occurred in 10% of respondents. Lesser degrees of mild and moderate erectile dysfunction occurred in 17% and 25%, respectively. In the National Health and Social Life Survey (NHSLS), a nationally representative probability sample of men and women aged 18±59 y, 3 10.4% of men reported being unable to achieve or maintain an erection during the past year (corresponding to the proportion of men in the MMAS reporting complete erectile dysfunction). Both studies observed a strong relationship to age. Although the prevalence of mild erectile dysfunction in the MMAS remained constant (17%) between the ages of 40 and 70 y, there was a doubling in the number of men reporting moderate erectile dysfunction (17%±34%) and a tripling of complete erectile dysfunction (5%± 15%) (Figure 1 ). If the MMAS data are extrapolated, there are an estimated 18±30 million American men who are affected by erectile dysfunction.
Erectile dysfunction is strongly related to physical and psychological health. Among the major predictors of erectile dysfunction observed in the MMAS, 2 diabetes mellitus, heart disease, hypertension and decreased HDL levels were all associated with increased risk for the disorder. Medications for diabetes, hypertension and cardiovascular disease are other major risk factors. In addition, there is a higher prevalence of erectile dysfunction among men who have undergone radiation or surgery for prostate cancer, 4, 5 or who have a lower spinal cord injury. 6 The psychological correlates of erectile dysfunction include depression and anger. 2, 7 The NHSLS found a higher rate of erectile dif®culties among men who reported poor to fair health, and among men experiencing stress from unemployment or other causes. 3 Despite its increasing prevalence among older men, erectile dysfunction is not considered a normal or inevitable part of the aging process. It is rarely (in`5% of cases) due to aging-related hypogonadism, 8, 9 although the relationship between erectile dysfunction and age-related declines in androgen remains controversial. 10 Basic research on the neurovascular mechanisms has contributed greatly to our understanding of normal and pathological processes of erection.
11±13
There is increasing evidence that the state of trabecular smooth muscle contractility is regulated by a delicate balance between neurotransmitter and vasoactive substances mediating erectile tissue contraction (consistent with¯accidity) and relaxation (consistent with erection).
14 The nonadrenergic-noncholinergic neurotransmitter nitric oxide (NO) has been found to play a major role in inducing trabecular smooth muscle relaxation. Nitric oxide diffuses across smooth muscle cell membranes and binds to soluble guanylate cyclase. The resultant increase in intracellular cyclic guanosine monophosphate (cGMP) leads to binding of cGMP to cGMP-dependent protein kinases (PKG) and to cGMP dependent ion channels. The lowered intracellular calcium and activation of myosin light chain phosphatases, results in inhibition of smooth muscle contractility and enhancement of penile erection ( Figure 2 ). Multiple vasoactive agents, including vasoactive intestinal polypeptide (VIP), prostaglandin E1 (PGE1), forskolin, phosphodiesterase inhibitors and alpha adrenergic receptor antagonists affect smooth muscle contractility, each via a speci®c mechanism. 15 Ultimately, all act by changes in intracellular calcium and modulation of speci®c smooth muscle myosin light chain kinases (MLCK) and myosin light chain phosphatases (MLCP). These enzymes rapidly change the state of myosin phosphorylation and result in either smooth muscle contraction (¯accidity) or relaxation (erection). The role of central nervous system and spinal mechanisms has also been elucidated in recent studies 16 . Understanding of these biochemical and neural mechanisms regulating erection has allowed for the rational development of new pharmacologic strategies for the management of erectile dysfunction.
The recent advent of safe and effective oral therapy 17, 18 has greatly increased the number of patients seeking treatment and has signi®cantly altered the medical management of the disorder. Figure 1 Prevalence of erectile dysfunction in a communitybased sample of 40±70-year-old men. A strong age-related association with erectile dysfunction was noted across the study, with additional risk factors of diabetes, cardiovascular disease, cardiovascular drugs, smoking and depression. Figure 2 The local control of smooth muscle activity is regulated by contraction and relaxation forces exerted via speci®c neurotransmitter and vasoactive mechanisms. Nitric oxide (NO) is the principal nonadrenergic noncholinergic (NANC) neurotransmitter mediating corporal smooth muscle relaxation. Following intracellular diffusion, NO activates guanylate cyclase (GC), resulting in an increase in cyclic GMP and sequestration and extracellular migration of calcium. This process leads directly to smooth muscle relaxation. Cyclic GMP is inactivated by phosphodiesterase V (PDE 5). Penile smooth muscle contraction, in turn, is mediated by release of norepinephrine (NE) from adrenergic receptor cells and endothelial-derived endothelin, both of which are associated with increases in intracellular calcium levels. Norepinephrine effects on penile smooth muscle tissue contraction are mediated through the combined effects of cyclic AMP (cAMP) and release of a prostaglandin inhibitor (IP3).
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Historically the province of urologists and mental health professionals, erectile dysfunction is currently managed predominantly in the primary care setting. Recognizing this sudden and dramatic shift in practice patterns, a multidisciplinary panel of experts was convened to develop consensus on de®nition and classi®cation of the disorder, appropriate use of diagnostic assessment options, and guidelines for the treatment of erectile dysfunction by primary care physicians. Despite the increasing role of primary care physicians, strong emphasis was placed on the need for a multidisciplinary approach and the value of specialist consultation in well-de®ned situations. The consensus panel was drawn from a variety of specialty ®elds involved in the care of erectile dysfunction patients, including internal medicine, family practice, endocrinology, gerontology, diabetology, psychology, psychiatry, and urology. The core positions of the panel were developed by means of a three-stage process which included: (i) an initial consensus conference, (ii) focus group discussions with primary care practitioners, and (iii) expert panel review and formulation of clinical guidelines. Prior to the initial consensus conference, panel members reviewed relevant peer review articles (1988±1997) concerning physiology, pathophysiology, de®nition, classi®cation, epidemiology, diagnosis and treatment of erectile dysfunction. During subsequent meetings, criteria for diagnostic and treatment decision-making were evaluated by means of a modi®ed Delphi method, a medical decision-making and technology assessment procedure adapted from the Rand Corporation. 19, 20 The core positions and recommendations of the consensus panel were then presented to groups of primary care physicians for assessment of clinical utility. Modi®cations were made in response to primary care feedback and subsequent exert panel review. Six core positions and a new management algorithm for erectile dysfunction were formulated as follows (Figure 3) . Position 1. The identi®cation of erectile dysfunction is based upon a functional de®nition of the disorder, including classi®cation according to onset, severity and etiology. The cornerstone of initial evaluation is a comprehensive sexual, medical and psychosocial history. This history, along with a focused physical examination and selected laboratory tests, is strongly recommended in all cases.
Erectile dysfunction is de®ned as the persistent or repeated inability, for at least three months duration, to attain andaor maintain an erection suf®cient for satisfactory sexual performance (in the absence of an ejaculatory disorder, such as premature ejaculation). This de®nition closely parallels an earlier NIH consensus conference de®nition. 1 Key elements in the de®nition are: the persistence of the complaint for a period of at least three months (although individual circumstances may be taken into consideration, particularly following a surgical or traumatic cause), the ability of the patient to both achieve and maintain an erection in the presence of adequate sexual stimulation, and ®nally, the attainment of satisfactory sexual performance. The de®nition is based upon the patient's self-report in conjunction with a detailed sexual, medical and psychosocial history. For patients who meet the de®nition of erectile dysfunction, the initial assessment should include a careful evaluation of the impact of the problem on both the patient and partner. Questions or concerns related to sexual function should be explored with all new patients.
Following problem identi®cation, erectile dysfunction may be classi®ed according to severity, etiology and onset. The classi®cation process aids the physician in case formulation, patient assessment and communication, and consultation with other medical specialists. The severity of erectile dysfunction may be mild, moderate or severea complete. Mild erectile dysfunction refers to a relatively slight or intermittent loss of penile rigidity. Moderate and severe erectile dysfunction refer to increasing degrees of loss of penile rigidity and the associated impact on sexual activity.
Etiology is commonly divided into psychogenic, organic or mixed categories. Psychogenic erectile dysfunction is associated with a presumed psychological or interpersonal determinant, while organic erectile dysfunction is due to the effects of speci®c endocrinologic, neurolgic or vascular etiologies. Psychological or interpersonal factors frequently co-exist with organic causes. This may occur even in clear cut organic cases, such as the diabetic or post-radical prostatectomy patient. Primary erectile dysfunction occurs in men who have never been able to attain andaor maintain an erection for satisfactory sexual performance. Potential causes include deep-seated psychological con¯icts or perinealapelvic trauma. Secondary erectile dysfunction occurs in men who have a past history of satisfactory sexual performance.
The essential ®rst step in the management of erectile dysfunction is the taking of a comprehensive sexual, medical and psychosocial history (Table 1) . 21, 22 Clinicians should pay special attention to the sensitivity of the topic and to their patients' comfort level in discussing sexual issues and concerns. The history taking is also an opportunity for the physician to initiate patient and partner education and to facilitate communication.
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Outcomes related to this step in the process include: (i) characterization of the presenting problem, including duration and severity; (ii) assessment of the need for additional testing; and (iii) decision-making about referral or multidisciplinary involvement.
A focused physical examination should be performed on every patient with erectile dysfunction. This examination does not differ substantially from routine primary care practice. However, greater emphasis is placed on the genito-urinary, endocrine, vascular and neurologic systems. 22 The physical examination may corroborate aspects of the medical history (for example poor peripheral circulation), and may occasionally reveal unsuspected physical ®ndings (for example Peyronie's plaques, small testes, prostate cancer). The physical examination also provides an excellent opportunity for patient education and reassurance regarding normal genital anatomy.
Selective laboratory testing is recommended in all cases. An investigation of the hypothalamic± pituitary±gonadal axis via assessment of androgenic status and prolactin levels is important. 10, 23 There is disagreement about the relative value of the various testosterone assays, including total, free and bioavailable testosterone. 24 However, strong consensus exists that at least one of these assays should be performed. A serum prolactin determination should be obtained. Although the test may be of low yield, an elevated serum prolactin suggests a pituitary adenoma, a potentially life-threatening and treatable cause of erectile dysfunction. Standard serum chemistries, CBC and lipid pro®les may be of value and should be obtained, if not performed in the past year. Serum TSH determination may also be of value, as both hyper-and hypothyroidism have a high prevalence of erectile dysfunction. 10 Finally, a serum PSA may be indicated based upon the patient's age and relative risk status. 25, 26 Upon completion of the ®rst stage in the process, the physician should be able to determine the medical status of the patient, to identify and characterize the erectile dysfunction, and to assess the need for additional testing and referral. Patient needs, expectations and priorities are an essential element in this assessment, as patients vary greatly in their acceptance of medical treatment for sexual disorders. Another important goal in this phase is for the physician to foster a therapeutic alliance with the patient and, if possible, with the patient's partner. Although not always possible on the ®rst visit, every effort should be made to involve the patient's partner early on in the process.
Position 2. Patient and partner education are essential components of the management of erectile dysfunction. They facilitate the patient's and partner's understanding of the disorder, the interpretation of diagnostic tests, and the rational selection of treatment options. Careful attention to topics and issues for education is recommended in all cases.
Patient education is important in fostering a sound therapeutic relationship, facilitating patient±phy-sician and patient±partner communication, and enhancing patient compliance. Studies have shown that patient±physician communication about sexual issues is generally lacking, 27, 28 and fewer than 20% of male patients discuss sexual problems or concerns with their physician. 3 It should be emphasized that educational needs vary considerably from one patient to another, and that educational interventions should be tailored to meet the speci®c background and needs of each individual. Topics and issues to be addressed in patient and partner education include: (i) anatomy and physiology of sexual response, (ii) causes of erectile dysfunction and associated risk factors, including prescription drug effects and lifestyle factors (such as smoking, alcohol and substance abuse), (iii) initial assessment and diagnostic testing results, and (iv) treatment options, including potential risks and bene®ts in the context of the overall health status of the patient. The educational process also provides an opportunity for exploration of patient and partner expectations Position 3. While the majority of patients with erectile dysfunction can be managed within the primary care setting, speci®c circumstances may dictate the need for specialist referral. Consensus guidelines are provided for such testing and referral indications. Primary care physicians are strongly urged to take these indications into consideration in selected cases.
Erectile dysfunction may be the presenting complaint in an individual with major medical or psychiatric disease, or the circumstances of the disorder may warrant a specialist consultation or referral for diagnostic testing. Indications for referral or consultation may arise at the time of the initial evaluation or during the course of treatment or follow-up. Referral indications include: (i) younger patients with a history of pelvicaperineal trauma, who will bene®t from more specialized urologic studies and potentially curative vascular surgery, (ii) patients with signi®cant penile curvature (for example Peyronie's disease, congenital deformity) that may require surgical correction, (iii) complicated endocrinopathies (such as secondary hypogonadism, pituitary adenoma), (iv) complicated psychiatric or psychosexual disorders (such as refractory depression, hypoactive sexual desire), and (v) cases requiring vascular or neurosurgical assessment (for example possible aortic aneurysm, lumbosacral disc disease). Additionally, specialist referral may be indicated for further diagnostic testing at the request of the patient, his physician or for medico-legal reasons (for example workman's compensation claims).
Among the speci®c tests most commonly used are: (i) assessment of nocturnal penile tumescence and rigidity (NPTR), (ii) vascular studies, such as penile injection, ultrasound, and cavernosometry, (iii) neurologic studies, such as biothesiometry and evoked potential testing, (iv) endocrinologic studies, including thyroid function studies and pituitary imaging, and (v) specialized psychodiagnostic evaluation. A large body of literature exists concerning the rationale, methodology and outcomes related to the use of these tests. 29±32 When referring patients for specialized testing or consultation, care should be taken that patients are fully informed about the rationale and potential outcomes of such referrals. Results of specialized testing or consultation should be carefully reviewed with the patient at follow-up. The process of care model for erectile dysfunction
The Process of Care Consensus Panel bene®ts of risk factor modi®cation and lifestyle behavior changes are not documented, good clinical practice mandates attention to these issues either prior to, or along with direct therapies for erectile dysfunction. Prescription and nonprescription drugs are frequently implicated in erectile dysfunction, although the exact mechanisms are complex and not well understood. 33 Clinical reports are typically anecdotal, and rarely involve rechallenge with the implicated drug. There is also wide variability in patients' susceptibility to adverse sexual effects, and the clinical picture is often confounded by the presence of medical illness or lifestyle factors. In addition to their effects on erectile function, prescription drugs may adversely effect other sexual functions, including libido, orgasm and ejaculation. Prescription drugs most commonly associated with erectile dysfunction per se are the antihypertensives, 34, 35 antiarrythmics, 36 and antidepressants. 37, 38 Among the antihypertensives, thiazide diuretics and beta-blockers have been most commonly associated with erectile dif®culties in men. Digoxin is the antiarrythmic most likely to cause erectile dysfunction due to its inhibition of sodiumapotassium ATPase, 36 and possibly its weak estrogenic effects. Antidepressant and antipsychotic agents, particularly tricyclics, selective-serotonin reuptake inhibitors (SSRIs) and neuroleptics, are frequently associated with erectile dysfunction, as well as ejaculatory, orgasm and libido dif®culties. 38 Additionally, the use of recreational drugs, including alcohol, marijuana, cocaine and other narcotics, should be considered as an important and potentially modi®able risk factor. 33 In general, modi®cation or substitution of medications represents a viable initial management option for many patients prior to, or in conjunction with, direct intervention for erectile dysfunction.
Hypogonadism and androgen (testosterone) de®-ciency is a potentially reversible cause of erectile dysfunction. 10 Although generally uncommon, the prevalence of hypogonadism increases in men in the geriatric age range. Testosterone de®ciency may occur either as a result of primary testicular failure (primary hypogonadism) or secondary to pituitaryahypothalamic causes (hypogonadotrophic hypogonadism). In older men, the majority of cases of hypogonadism have both a testicular and pituitary contribution. Testosterone replacement is effectively and safely accomplished by parenteral or topical delivery 39 and should be employed very selectively. Testosterone replacement therapy is contraindicated in men with a history of prostate or breast carcinoma or with symptoms of bladder outlet obstruction. Prior to initiating replacement therapy, a digital rectal examination and serum PSA should be performed. Patients receiving androgen therapy should be monitored for a clinical response, as well as intermittent serum testosterone levels, liver function status, PSA, and most importantly, serum hematocrit levels. The latter is indicative of secondary polycythemia, and should be reassessed every six months. Testosterone replacement is a treatment for hypogonadism, and is not always effective in managing the associated erectile dysfunction. Other pathological mechanisms, such as vascular disease or depression, are frequently observed in older patients with hypogonadism and may need to be separately addressed. Additional reversible endocrinologic causes of erectile dysfunction may be associated with pituitary or thyroid abnormalities. 10, 23 Pelvic or perineal trauma in younger patients (that is,`45 y of age) may be associated with focal arterial occlusive lesions that are surgically correctable. The associated erectile dysfunction can be reversed in selected cases by reconstructive microvascular surgery. 40 In cases where a focal arterial occlusion is demonstrated by penile pharmacoarteriography, a surgical revascularization procedure employing a neoarterial source (such as the inferior epigastric artery) to deliver blood to the corpora cavernosa (via the dorsal artery and its penetrating branches), may be the preferred intervention option. Penile revascularization is associated with a 60±70% long-term (that is, 5 y) success rate and few complications. 41 Position 5. When speci®c therapies for erectile dysfunction are required, a step-wise treatment approach should be followed. This approach divides existing treatments into ®rst, second and third-line therapies, based on such criteria as ease of administration, reversibility, invasiveness and cost. Treatment decisionmaking according to this model is strongly recommended in the primary care setting.
The proposed treatment model incorporates a stepwise progression of therapy interventions for erectile dysfunction. This step-wise approach is based on the essential criteria of: (i) ease of administration, (ii) reversibility, (iii) invasiveness, and (iv) cost. The medical condition and safety of the individual, as well as patient and partner preferences should be considered in all cases. First line therapies may be used as single interventions or in combination (for example oral medication plus counseling). Second and third line therapies are generally reserved for patients who show insuf®cient response to one or more ®rst line therapies.
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First-line therapy options
First-line therapy options include oral erectogenic agents, vacuum constriction devices, and psychosexual or couples therapy. These ®rst-line interventions have relatively low risk pro®les and are appropriate for a broad range of patients in the primary care setting. The selection of each ®rst-line treatment option should be based upon patient and partner preference, medical indications and contraindications, cost and patient reimbursement factors.
(i) Oral erectogenic drugs Sildena®l citrate is a potent and selective inhibitor of type V phosphodiesterase, the predominant isoform of the enzyme found in human penile erectile tissue, and the ®rst oral agent to be speci®cally approved for the treatment of erectile dysfunction. 17, 18 Sildena®l is administered`on demand' in dosages of 25, 50, or 100 mg, and is effective in enhancing erections following sexual stimulation 30±90 minutes after administration. Unlike intracorporal injections or vacuum constriction devices, sildena®l is only effective in the presence of sexual stimulation. The most common side effects associated with sildena®l include headaches (16%),¯ushing (10%), dyspepsia (7%) and nasal congestion (4%). In doses up to 100 mg, approximately 3% of men report mild alterations in color vision (blue hue), visual brightnessasensitivity, or blurred vision. 17 Sildena®l is absolutely contraindicated for men receiving nitrate therapy including short or long acting agents delivered by oral, sublingual, transnasal or topical administration. It should also be employed with caution, if at all, in men with unstable, ischemic cardiovascular disease. Invest-igational oral agents for erectile dysfunction include sublingual apomorphine, 42 oral phentolamine 43 and other phosphodiesterase inhibitors. Guidelines have recently been published on the use of sildena®l in patients with cardiovascular disease. 44 (ii) Vacuum constriction device (VCD) therapy VCD therapy is a well-established, non-invasive treatment that has recently been approved by the FDA for over the counter distribution. 45, 46 It provides a useful treatment alternative for patients for whom pharmacological therapies are contraindicated, or who do not desire other interventions. Vacuum constriction devices apply a negative pressure to the pendulous penis, thus drawing venous blood into the penis, which is then retained by the application of an elastic constriction band at the base of the penis. The adverse events occasionally associated with VCD therapy include penile pain, numbness, bruising, and delayed ejaculation. 45 (iii) Psychosexual therapy For cases involving a signi®cant psychological or interpersonal component, psychosexual therapy can be utilized as an additional ®rst-line therapy, either in isolation or in combination with other treatments. 47, 48 A course of therapy typically includes 6 to 14 visits, usually weekly or biweekly, during which speci®c psychological or interpersonal factors are addressed. Factors that frequently interfere with sexual satisfaction are relationship distress, sexual performance concerns, and dysfunctional communication patterns. Independent, brief sex therapy consists of in-session discussion and at-home exercises speci®c to the person and relationship. Therapy can be conducted with the man alone, although it is preferable to include both partners if the patient is involved in an ongoing relationship. Sexual therapy has been associated with variable outcomes in clinical trials. 49 
Second-line therapy options
Second-line therapies should be selected based upon: (i) failure, insuf®cient response or adverse side effects associated with one or more of the ®rst-line therapies, or (ii) patientapartner preferences. These interventions consist of intraurethral administration or intracavernosal injection of alprostadil. Although widely utilized, these treatments are associated with variable ef®cacy, a high patient discontinuation rate, possible risk of side effects, and moderately high cost.
(i) Intraurethral alprostadil Alprostadil (prostaglandin E 1 ) may be administered intraurethrally in the form of a semi-solid pellet inserted by means of a special applicator. To obtain an effective concentration of alprostadil in the corpora cavernosa, 125±1000 mg of the drug are delivered by the device to the urethra. Systemic absorption is likely to occur. In a mixed group of patients with organic erectile dysfunction, 65% of men receiving intraurethral alprostadil responded with a ®rm erection when tested in the of®ce, and 50% of administrations to that subset resulted in at least one episode of successful intercourse in the home setting. 50 Side-effects associated with the intraurethral administration of alprostadil include penile pain and hypotension. Prolonged erections and penile ®brosis are rare, 51 although the clinical success rate is low. 52 (ii) Intracavernosal injection therapy Prior to the approval of sildena®l, intracavernosal selfinjection was the most common medical therapy for erectile dysfunction. 53, 54 The two FDA
The Process of Care Consensus Panel approved drugs for intracavernosal injection, alprostadil sterile powder and alprostadil alfadex, are both synthetic formulations of prostaglandin E 1 . Injection therapy is effective in most cases of erectile dysfunction, regardless of etiology. It is contraindicated in men with a history of hypersensitivity to the drug employed, in men at risk for priapism (for example, in sickle cell disease, hypercoagulable states) and in men receiving monoamine oxidase inhibitors. The effective therapeutic range is between 1 and 60 mg, with the majority of responders (85%) requiring less than 20 mg. In general, intracavernosal injection therapy with alprostadil is effective in 70%±80% of patients, although discontinuation rates are high in most studies. Side-effects include prolonged erections or priapism, penile pain, and ®brosis with chronic use. In addition to single-agent injection therapy, various combinations of alprostadil, phentolamine andaor papaverine are widely employed in urological practice. 54 
Third-line therapy options
Third-line therapy, according to the proposed model, consists of surgical implantation of a penile prosthesis. For select cases of severe, treatmentrefractory erectile dysfunction, for patients who fail pharmacologic therapy or who prefer a permanent solution for the problem, surgical implantation of a semi-rigid or in¯atable penile prosthesis is available. 55 The in¯atable penile prosthesis provides a more aesthetic erection and better concealment than semi-rigid prostheses, although there is an increased rate of mechanical failure and complications (5±20%) with the former. Despite the cost, invasiveness and potential medical complications involved, penile implant surgery has been associated with high rates of patient satisfaction in previous studies. 55, 56 These studies were conducted prior to the advent of newer forms of therapy, however.
An algorithm for diagnosis and treatment of erectile dysfunction is shown in Figure 3 . In addition to the speci®c processes and actions shown, reassessment and follow-up should be conducted at regular intervals as an integral part of the patient's ongoing care. Issues to be addressed include: (i) medical and psychosocial reassessment, (ii) potential adverse drug reactions or drug interaction effects, (iii) the need for dosage titration or substitution of another intervention, and (iv) patient concerns regarding treatment administration, presence of other sexual dysfunctions (for example premature ejaculation), partner issues (for example anorgasmia), or lifestyle factors. Patients may also change treatment preferences, seek new information, or wish to reevaluate their current treatment choices.
Position 6. Despite the progress achieved in recent years, additional research on the causes and treatment of erectile dysfunction is strongly recommended. Further research is needed on the role of aging-and diseaserelated factors in the etiology of the disorder, as well as the potential impact of lifestyle modi®cation in the prevention and treatment of erectile dysfunction. Studies on the molecular and cellular basis of erection hold promise for the development of speci®c gene therapies, and new classes of oral and topical erectogenic agents await investigation. Finally, research into the mechanisms, diagnosis and treatment of female sexual dysfunction is urgently needed.
While the association between erectile dysfunction and aging has been demonstrated in several studies, 2,3 the role of speci®c mechanisms and underlying pathophysiological processes has yet to be delineated. The ®nal expression of a range of pathophysiological insults to the corporal tissue appears to be that of ®brosis. Accelerated collagen synthesis and retarded collagen degradation have been described in association with ischemia and hypoxemia in animal models. 57 In-vitro and invivo studies have implicated transforming growth factor beta-1 as a mediator of corporal ®brosis. The role of other cytokines in this process is less clearly understood. Additionally, signi®cant molecular biological research is required to elucidate the regulation and expression of genes that control such critical molecules as nitric oxide synthase, type 5 phosphodiesterase, maxi-K channels and TGF beta-1. This understanding would facilitate future targeting of pharmacologic and gene therapies.
Epidemiological studies have implicated the use of prescription and non-prescription drugs, in addition to lifestyle factors (for example cigarette smoking, stress) as important risk factors for the development of erectile dysfunction. 2, 3 However, no prospective studies have evaluated the effectiveness of medication changes or lifestyle modi®cation in the prevention or treatment of the disorder. Studies are urgently needed on the speci®c role of cardiovascular drugs (such as antihypertensives, anticholesterolemics) in the etiology and maintenance of erectile dysfunction, as well as the therapeutic bene®t of altering patients' medication regimens. Given the large
The process of care model for erectile dysfunction The Process of Care Consensus Panel number of men currently maintained on cardiovascular drugs, and the high rate of associated erectile dysfunction, the issue of medication change or substitution has important public health implications. Sexual dysfunction is a commonly cited reason for non-compliance or withdrawal from treatment in men taking antihypertensive or antidepressant medications. 38, 58 New oral and topical therapies for erectile dysfunction are in advanced stages of development. In the next two years, it is anticipated that two additional oral agents (oral phentolamine, sublingual apomorphine) will be approved, and several topical agents are under investigation. New injectable combination drugs are in development, and combinations of oral, or oral and injectable, drugs have been proposed for the treatment of refractory cases. Research on psychosexual therapy outcomes, either alone or in combination with pharmacological therapy, is also urgently needed.
Although erectile dysfunction is not associated with a speci®c genetic defect, a variety of molecular biological and gene therapy approaches have recently been proposed. 59 Since erectile function is dependent upon the state of relaxation of the corporal smooth muscle, any therapy that promotes smooth muscle relaxation may be of clinical value in the treatment of the disorder. Gene therapy approaches have been investigated in several animal models, in which smooth muscle relaxation is effected by nitric oxide synthase induction (inducable nos gene), or by the induction of smooth muscle maxi-K channels causing hyper-polarization (hslo gene). 59 The penis is an external organ with a syncytium of smooth muscle tissue that is readily available for isolated introduction of genetic material, the effects of which may be greatly magni®ed due to the plethora of interconnected cells in this syncytium. The low turnover rate of this smooth muscle tissue suggests that the therapeutic effects of gene introduction could potentially endure for several months at a time. Clearly, further research is needed to determine the clinical applicability of these early gene therapy approaches.
Finally, further attention needs to be given to interpersonal issues and the role of the sexual partner. 60, 61 During the evaluation of erectile dysfunction it is not uncommon for the patient to be accompanied by his partner, who frequently presents with sexual issues or problems of hisaher own. Little attention has been given to the in¯uence of partner variables generally, and the potential contribution of sexual dysfunction in the female partner has only recently been raised. 62 It is hoped that research efforts in the emerging ®eld of male and female sexual dysfunction will broaden to incorporate new diagnostic and treatment options for both members of the couple.
Conclusions
A new era has begun in the medical management of male erectile dysfunction. From the advent of penile implantation surgery in the 1970s, to intracorporal injection of vasoactive agents in the 1980s and intraurethral insertion of alprostadil in 1995, the ®eld has progressed rapidly to offer patients a wide range of treatment interventions and diagnostic options. Recently, important research on the cellular mechanisms of erections has led to signi®cant pharmacological and therapeutic breakthroughs. New medications offer not only the promise of safe, effective and acceptable treatments, but also suggest a far-reaching change in the process of care and clinical practice patterns in this emerging ®eld of sexual dysfunction management.
Male erectile dysfunction affects millions of men and their sexual partners. With expanding public information about new medications, physicians are likely to encounter ever-increasing numbers of these patients seeking treatment. This will undoubtedly be true for primary care physicians, as well as for specialists. To assist physicians in providing optimal, evidence-based care for their patients, a consensus model has been developed for diagnostic assessment and treatment of erectile dysfunction. The core elements of the model are: (i) a goal-oriented approach to diagnosis and treatment, (ii) emphasis on clinical history taking and a focused physical examination; (iii) specialized testing and referral in pre-de®ned situations, (iv) step-wise management approach with ranking of treatment options, and (v) incorporation of patient needs and preferences wherever possible in the decision-making process.
Along with greater clinical sophistication, it is hoped that physicians will be able to provide the emotional support and empathy that sexually dysfunctional patients often require. Despite increased public awareness of the topic, there are few aspects of human behavior that have as much capacity to affect our self-esteem and overall sense of well-being.
Editor's Note
Consensus or position papers are important to publish as rapidly as possible and to be discussed as broadly as possible. This procedure de®nitely brings openness and transparency for the peer group and makes it possible to develop one's own thoughts for the individual.
Furthermore as the therapeutic possibilities within the ®eld of erectile dysfunction rapidly have changed into non-invasive procedures, new and for the moment, more-or-less unprepared primary care physicians are faced with a sexual symptom complex that needs professional handling.
This position paper facilitates the understanding of the road which could be followed. A group of eleven US-specialists within male sexual dysfuction has produced the recommendations based on the fact of the new pharmacological approaches, which only seems to be the beginning of an explosive new era.
Members of the editorial board of the International Journal of Impotence Research (from outside the US) have provided some comments in order to emphasize that traditions, ethical and social conditions are to be incorporated in our understanding of a goal-oriented approach.
Whenever a group of highly selected, knowledgeable specialists is gathered to work on a speci®c medical approach to treatment the traditional questions have to be asked: Who selected, who participated, who sponsored? An eternal dilemma for those who have the energy and take the initiatives. Although the questions are relevant, the key issue is that disclosure, transparency and open debate follow.
Soon to appear is the 1st International Consultation on Erectile Dysfunction which comprises the work of 18 committees. An extensive presentation by the committees, followed by open discussion before a set of recommendations are formulated, will take place in Paris, July 1±3, 1999.
With the present Position Paper as a forerunner, a major international group should be able to work out a complete set of contemporary professional points of view in relation to erectile dysfunction.
Human sexuality has come out in the open in an hitherto unheard way just before the new Millennium and the professionals have to hurry up in order to be able to tackle the new patient's demands in a proper way.
Gorm Wagner

Editorial Comments
The recent emergence of effective oral treatments for male sexual dysfunction has greatly increased the number of patients seeking help and has changed the approach towards them. Following an era of a small scale specialised monodisciplinary and aetiology-directed approach in the 1980s, to date the approach of male sexual dysfunction has become multidisciplinary and goal-directed, centred around the primary-care physician. The choice of treatment is decided on factors such as ease of administration, reversibility, invasiveness, costs and last but not least the patient's and partner's choice.
This change of culture, in the literature characterised in terms of`medicalisation of male sexuality' or`male sexual emancipation' was boosted by the fact that the oral treatments are bene®cial irrespective of aetiology, the increase of
